Vagus nerve stimulation devices deliver electrical impulses to the vagus nerve to treat conditions ranging from epilepsy to rheumatoid arthritis. The clinical evidence behind them is uneven — strong for some indications, weak or absent for others. What separates VNS from most neuromodulation technologies is the breadth of its proven and emerging applications, each working through a different downstream mechanism: seizure suppression through cortical desynchronisation, mood regulation through locus coeruleus activation, inflammation control through the cholinergic anti-inflammatory pathway, and motor recovery through plasticity gating. This guide covers what VNS devices have been shown to do, with the clinical data behind each benefit, and where the evidence falls short.

Epilepsy: The Longest Track Record

VNS was first FDA-approved for drug-resistant epilepsy in 1997, making it the indication with the most long-term data. The mechanism involves vagal afferent fibres projecting to the nucleus tractus solitarius, which connects to widespread cortical and subcortical networks — the same networks involved in seizure generation and propagation. Stimulating these pathways modulates abnormal synchronisation in epileptic circuits.

The clinical data show a pattern unique to VNS: effectiveness improves over time rather than diminishing. In the pivotal trials, approximately 25-30% of patients achieved a 50% or greater seizure reduction within the first three months. By 1-2 years, that responder rate climbs to approximately 50%. A subset of patients — roughly 5-8% — eventually achieve seizure freedom. A 2023 systematic review in Frontiers in Neurology confirmed this progressive improvement pattern across multiple studies, with responder rates continuing to increase through year three and beyond.

VNS does not replace anti-seizure medications. It is approved as adjunctive therapy, meaning it is added to existing medications when those medications provide insufficient control. In practice, some patients are able to reduce their medication burden after sustained VNS therapy, but this should be managed by their neurologist. The newer generation of implanted VNS devices (LivaNova’s SenTiva and AspireSR) include closed-loop features that detect heart rate changes associated with seizure onset and automatically deliver additional stimulation — a refinement that may improve acute seizure management.

Depression: Slow-Building but Durable

VNS received FDA approval for treatment-resistant depression in 2005. The vagus nerve projects to the locus coeruleus and dorsal raphe nucleus — the brain’s primary sources of norepinephrine and serotonin — and chronic VNS modulates activity in these regions and their downstream mood-regulation circuits.

The benefit profile in depression differs fundamentally from antidepressant medication. Response typically takes months rather than weeks to emerge. In clinical studies, response rates at 3 months are approximately 15-20%, but by 12 months they rise to roughly 30%, and by 2 years they exceed 40% in some registries. Critically, patients who respond tend to maintain their improvement — the durability of VNS for depression contrasts with the relapse rates commonly seen after medication or psychotherapy response.

The practical limitation is that VNS for depression requires surgical implantation of the same device used for epilepsy, and the slow onset of benefit means patients must commit to months of therapy before knowing whether it will help. This restricts its use to patients who have failed multiple medication trials, psychotherapy, and often electroconvulsive therapy (ECT). It is not a first-line or even second-line treatment.

Migraine and Cluster Headache: Non-Invasive VNS

The gammaCore device (electroCore) is the most established non-invasive VNS device, FDA-cleared for episodic cluster headache (2017), migraine (2018), and paroxysmal hemicrania. Unlike implanted VNS, gammaCore is a handheld device applied to the neck over the vagus nerve, delivering stimulation through the skin.

For cluster headache, the ACT1 trial showed that gammaCore significantly outperformed sham stimulation for acute treatment of episodic cluster attacks, with a pain-free rate at 15 minutes of approximately 34% versus 10% for sham. For migraine prevention, a University of Bonn study found that gammaCore reduced the number of migraine days by approximately 3.6 per month compared to baseline after two months of use. The PREMIUM II trial met its primary endpoint, showing significant reduction in monthly migraine days with gammaCore versus sham.

The mechanism involves vagal afferents modulating the trigeminocervical complex — the brainstem relay station for headache pain — and reducing levels of glutamate and CGRP, the neuropeptides that drive migraine and cluster attacks. The practical advantages are significant: no surgery, no systemic medication side effects, and no drug interactions. The limitation is that effect sizes are moderate — gammaCore helps a meaningful percentage of patients but is not a dramatic responder in most.

Rheumatoid Arthritis: Bioelectronic Medicine Arrives

In July 2025, the FDA approved SetPoint Medical’s implantable vagus nerve stimulator for rheumatoid arthritis — the first VNS device approved for an autoimmune condition. This approval represents the clinical validation of the cholinergic anti-inflammatory pathway, a mechanism Kevin Tracey and colleagues identified in the early 2000s: vagus nerve activation triggers acetylcholine release in the spleen, which binds to alpha-7 nicotinic receptors on macrophages and suppresses TNF, IL-1, and IL-6 production.

The SetPoint device is notably small — approximately the size of a vitamin tablet — and stimulates the vagus nerve for just 60 seconds once daily. In the pivotal trial of 242 RA patients who had failed biologic or targeted synthetic DMARDs, 35.2% achieved at least a 20% symptom reduction (ACR20 response). Serious adverse events occurred in fewer than 2% of participants. The device is now being commercially rolled out in select US cities, with broader availability planned for 2026.

The effect size is modest compared to biologic DMARDs (which typically achieve ACR20 rates of 60-70%), but the safety profile is dramatically better — no immunosuppression, no injection-site reactions, no increased infection risk. For patients who cannot tolerate or have exhausted conventional RA therapies, this represents a genuinely new treatment category. The broader implication is that the same anti-inflammatory mechanism may be applicable to other inflammatory conditions including Crohn’s disease, where trials are underway.

Stroke Rehabilitation: Paired VNS

The Vivistim system (MicroTransponder) received FDA approval in August 2021 for upper-limb motor rehabilitation after ischaemic stroke. It works on a different principle from other VNS applications: brief vagus nerve stimulation pulses are delivered during rehabilitation exercises, and the resulting release of acetylcholine and norepinephrine in the cortex gates plasticity — strengthening the neural connections being activated by the exercises.

In the pivotal trial of 108 patients across 19 sites in the US and UK, paired VNS plus rehabilitation improved upper-extremity Fugl-Meyer Assessment scores by an average of 5 points compared to 2.4 points with rehabilitation plus minimal stimulation (control). At 90 days after therapy, 47.2% of the VNS group had achieved a clinically meaningful improvement of 6 or more points, versus 23.6% of controls — effectively doubling the rate of meaningful motor recovery.

This is a conceptually important result because it demonstrates that VNS can enhance the brain’s response to rehabilitation rather than directly treating a condition. The same paired-VNS principle is now being tested for tinnitus (retraining the auditory cortex) and PTSD (pairing VNS with exposure therapy to enhance fear extinction learning).

Insomnia: Emerging Non-Invasive Evidence

Transcutaneous auricular VNS (taVNS) — stimulation of the vagus nerve’s auricular branch at the ear using surface electrodes — has shown promising results for chronic insomnia. A randomised controlled trial published in JAMA Network Open in December 2024 tested taVNS in 72 adults with chronic insomnia disorder. Active taVNS (30 minutes, twice daily, for eight weeks) improved Pittsburgh Sleep Quality Index scores by 8.2 points versus 3.9 points for sham stimulation — a between-group difference of 4.2 points, well above the 2.5-point minimal clinically important difference. Benefits were sustained across the 20-week study period.

The mechanism likely involves vagal afferents modulating the locus coeruleus-norepinephrine system, which regulates arousal and sleep-wake transitions. While this is a single trial with a modest sample size, it represents the highest-quality evidence to date for taVNS in any sleep indication.

Where the Evidence Falls Short

Several high-profile VNS applications have not delivered the expected results. The ANTHEM-HFrEF trial for heart failure enrolled only 532 of a planned 1,000 patients before the sponsor (LivaNova) stopped it for financial reasons. The primary endpoint — cardiovascular death or heart failure hospitalisation — showed no significant difference (HR 0.84, 95% CI 0.63-1.13), though quality of life scores favoured VNS. The question remains open but unanswered.

VNS for obesity, Alzheimer’s disease, and anxiety disorders remains at the preliminary investigation stage. Small pilot studies exist for each, but none has produced the large, controlled trial data needed to draw clinical conclusions. Patients considering VNS for these conditions should understand that they are entering experimental territory, not established therapy.

Consumer-grade taVNS devices marketed for general “vagal toning” and wellness are a separate category entirely. These devices have not undergone the clinical trials required for medical claims, their stimulation parameters vary widely, and the evidence supporting their use for specific health outcomes is limited. The gap between a medical-grade VNS device tested in rigorous trials and a consumer ear clip should not be underestimated.

VNS devices are reshaping treatment for conditions from epilepsy to rheumatoid arthritis, but understanding which benefits are proven and which are theoretical requires knowing the science behind the nerve itself. My Vagus Nerve & Me covers the full anatomy of the vagus nerve, the mechanisms behind electrical stimulation, and what the latest clinical evidence actually shows. Get My Vagus Nerve & Me eBook and make informed decisions about vagal health.

Keep reading

What Does a Vagus Nerve Stimulator Do?7 min read

A Captivating Snapshot of the Vagus Nerve14 min read

The Impact of the Apollo Vagus Nerve Stimulator on Health and Well-being12 min read